Loading
HKSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
HK$4.155
−HK$0.04 · -0.95%
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
Latest quote
HK$4.155
−HK$0.04 · -0.95%
Regular session · HKT · Market data may be delayed.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
Day range
Current HK$4.155
52-week range
Current HK$4.155
Regular session · HKT · Market data may be delayed.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
Day range
Current HK$4.155
52-week range
Current HK$4.155
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 5.48B CNY | 5.28B CNY | 5.45B CNY | 7.16B CNY | 6.37B CNY |
| Cost of goods sold | 3.74B CNY | 3.52B CNY | 3.65B CNY | 4.83B CNY | 4.33B CNY |
| Gross profit | 1.74B CNY | 1.76B CNY | 1.8B CNY | 2.33B CNY | 2.03B CNY |
| Research and development | 226.16M CNY | 212.04M CNY | 184.66M CNY | 252.14M CNY | 221.1M CNY |
| Selling, general, and administrative | 478.17M CNY | 454.67M CNY | 590.13M CNY | 665M CNY | 572.83M CNY |
| Operating expenses | 1.11B CNY | 1.01B CNY | 2.66B CNY | 1.21B CNY | 1.07B CNY |
| Interest income | 38.27M CNY | 44.37M CNY | 39.52M CNY | 54.14M CNY | 54.86M CNY |
| Interest expense | 71.44M CNY | 141.18M CNY | 223.22M CNY | 235.24M CNY | 201.63M CNY |
| Depreciation and amortization | 372.91M CNY | 331.05M CNY | 373.6M CNY | 307.66M CNY | 302.74M CNY |
| Operating income | 635.97M CNY | 741.31M CNY | −238.11M CNY | 1.14B CNY | 773.2M CNY |
| Net income | 349.49M CNY | 646.74M CNY | −783.26M CNY | 727.43M CNY | 240.79M CNY |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$0.2717
2025 complete year+50.9% since 2021
2026 partial: HK$0.166
HK$0.18
2,021
HK$0.0411
2,022
HK$0.1122
2,023
HK$0.2717
2,025
HK$0.166
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | May 27, 2026 | HK$0.166Annual | May 28, 2026 | Jun 18, 2026 |
Dividend | May 26, 2025 | HK$0.2717Annual | May 27, 2025 | Jul 22, 2025 |
Dividend | May 24, 2023 | HK$0.1122Annual | May 25, 2023 | Aug 15, 2023 |
Dividend | Jun 14, 2022 | HK$0.0411Annual | Jun 15, 2022 | Aug 15, 2022 |
Dividend | May 28, 2021 | HK$0.18Annual | May 31, 2021 | Jul 26, 2021 |
Ex-dividend May 27, 2026
HK$0.166
Annual
Record May 28, 2026 · Payment Jun 18, 2026
Ex-dividend May 26, 2025
HK$0.2717
Annual
Record May 27, 2025 · Payment Jul 22, 2025
Ex-dividend May 24, 2023
HK$0.1122
Annual
Record May 25, 2023 · Payment Aug 15, 2023
Ex-dividend Jun 14, 2022
HK$0.0411
Annual
Record Jun 15, 2022 · Payment Aug 15, 2022
Ex-dividend May 28, 2021
HK$0.18
Annual
Record May 31, 2021 · Payment Jul 26, 2021
Funds reporting this stock among their holdings, ordered by reported position size.
Dimensional - Emerging Markets Core Equity 2 ETFDFEM120.34K0.00%9.52B USD0.39%$39.40-0.66%
Dimensional - Emerging Core Equity Market ETFDFAE82.36K0.00%10.05B USD0.29%$38.98-0.46%
Dimensional World ex U.S. Core Equity 2 ETFDFAX50.54K0.00%12.5B USD0.28%$37.43-0.51%
Dimensional - Emerging Markets Value ETFDFEV40.38K0.00%2.18B USD0.46%$42.21-0.46%
Vanguard Total International Stock ETFVXUS11K—646.2B USD0.05%$85.69-0.41%
Vanguard Total World Stock ETFVT8.53K0.00%97.9B USD0.06%$158.03-0.44%Dimensional - Emerging Markets Core Equity 2 ETFDFEMDimensional - Emerging Core Equity Market ETFDFAEDimensional World ex U.S. Core Equity 2 ETFDFAXDimensional - Emerging Markets Value ETFDFEVVanguard Total International Stock ETFVXUSVanguard Total World Stock ETFVTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
